查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
分子腫瘤診斷市場 - 2018-2028年全球行業規模、佔有率、趨勢、競爭、機會和預測，按產品類型、技術、應用、癌症類型、終端用戶和地區細分
市場調查報告書
商品編碼
1309227

分子腫瘤診斷市場 - 2018-2028年全球行業規模、佔有率、趨勢、競爭、機會和預測，按產品類型、技術、應用、癌症類型、終端用戶和地區細分

Molecular Oncology Diagnostics Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Product Type, By Technology, By Application, By Cancer Type, By End User, By Region
出版日期: | 出版商: TechSci Research | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計在2024-2028 年的預測期內，全球分子腫瘤診斷市場將保持穩定的複合年成長率。這可歸因於癌症、心血管疾病和糖尿病等各種慢性疾病的發病率不斷上升。根據全球癌症觀察站（Global Cancer Observatory）的數據，2020 年全球新增癌症病例約為19,292,789 例，其中男性病例為10,065,305 例，女性病例為9,227,484 例。癌症是由於癌細胞不受控制地從內層向外層擴散而引起的。分子腫瘤學診斷是指診斷癌症的檢測。這些檢測用於識別遺傳物質、蛋白質或相關化學物質，並提供有關健康或疾病的資訊。然而，目前需要開發新的診斷方法和儀器，預計這將進一步推動分子腫瘤診斷市場的成長。

癌症發病率上升

癌症是世界上最常見的死亡原因之一。全球癌症病例的增加可能是腫瘤分子診斷市場成長的一個因素。根據美國癌症協會的數據，2021 年美國新增癌症病例180 萬例，癌症死亡病例60 萬例。由於癌細胞的擴散，醫學專家正在加大研發力度，開發有助於預防和治療癌症的治療和診斷服務。據美國癌症協會稱，肺癌、前列腺癌、腸癌和女性乳腺癌是全球四大癌症類型，佔所有新發癌症病例的43%。例如，美國癌症協會估計，到2022 年，美國將新增106 180 例結腸癌和44 850 例直腸癌。此外，根據美國癌症協會的2020 年報告，包括美國國家綜合癌症網路（NCCN）、美國臨床腫瘤學會（ASCO）和美國病理學家學會（CAP）在內的一些專業協會已經制定了生物標記物檢測和治療指南。因此，它們的治療或診斷成像技術將推動全球分子腫瘤診斷市場的成長。

技術進步

先進技術包括基因組學測序技術。例如，癌症基因組測序技術、計算分析、腫瘤模型以及現代癌症研究機構正在進行的創新和研究的進步促進了癌症及其突變的早期檢測。例如，2020 年6 月，美國食品和藥物管理局（FDA）批准了Cobas 表皮生長因子受體基因突變檢測試劑盒，這是一種用於檢測非小細胞肺癌患者的基因突變檢測試劑盒，它是一種即時檢測試劑盒，可以識別表皮生長因子受體基因中的抗癌突變和42 種突變。該分子檢驗由美國羅氏分子系統公司開發。

近期發展與產品上市

研究與開發（R&D）實踐和活動的快速發展推動了市場的成長，因為人們越來越需要開發新型診斷解決方案來治療癌症等危及生命的疾病。例如，2022年8月，Guardant Health公司擴大了其Guardant Reveal測試的使用範圍，開發出一種液體活體組織切片測試，用於殘留疾病檢測和復發監測，包括早期乳腺癌和肺癌。目前，乳腺癌和肺癌患者可以使用這種檢測方法，它也是唯一一種針對結直腸癌（CRC）的無組織檢測方法。

此外，2021 年12 月，QIAGEN 與Denovo Biopharma 合作開發了用於治療瀰漫大B 細胞淋巴瘤的輔助診斷檢測。該檢驗能確定哪些人具有Denovo 基因組標記1 (DGM1)，對Denovo 抗癌藥物DB102 有反應。

可用客製化：

有了給定的市場數據，TechSci Research 可以根據公司的具體需求提供客製化服務。報告可提供以下客製化選項：

公司資訊

  • 其他市場參與者（最多五家）的詳細分析和概況。

目錄

第1 章：產品概述

  • 市場定義
  • 市場範圍
    • 覆蓋市場
    • 研究年份
    • 主要市場細分

第2 章：研究方法

  • 研究目的
  • 基準方法
  • 主要行業合作夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第3 章：執行摘要

  • 市場概述
  • 主要市場細分概述
  • 主要市場參與者概述
  • 主要地區/國家概述
  • 市場驅動因素、挑戰和趨勢概述

第4章：客戶之聲

第5章：全球分子腫瘤診斷市場前景

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按產品類型（儀器、試劑盒和化驗、軟體）
    • 按技術（螢光原位雜合技術（FISH）、新一代測序（NGS）、聚合酶鏈反應（PCR）、免疫組化（IHC）、流式細胞術及其他技術）
    • 按應用（研究、臨床）
    • 按癌症類型（實體瘤（乳腺癌、卵巢癌、前列腺癌、肺癌、結直腸癌和其他實體瘤）、血癌（淋巴瘤、白血病、多發性骨髓瘤和其他血液惡性腫瘤）}分類
    • 按最終用戶（醫院和診斷中心、參考實驗室、製藥和生物技術公司、學術和研究機構）
    • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
    • 按公司（2022 年）
  • 市場地圖
    • 按產品類型
    • 按技術
    • 按應用
    • 按癌症類型
    • 按最終用戶
    • 按地區

第6章：北美分子腫瘤診斷市場前景

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按產品類型
    • 按技術
    • 按應用
    • 按癌症類型
    • 按最終用戶
    • 按國家
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7 章：歐洲分子腫瘤診斷市場前景

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按產品類型
    • 按技術
    • 按應用
    • 按癌症類型
    • 按最終用戶
    • 按國家
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8 章: 亞太地區分子腫瘤診斷市場前景

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按產品類型
    • 按技術
    • 按應用
    • 按癌症類型
    • 按最終用戶
    • 按國家
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞

第9 章: 南美分子腫瘤診斷市場前景

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按產品類型
    • 按技術
    • 按應用
    • 按癌症類型
    • 按最終用戶
    • 按國家
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10 章：中東和非洲分子腫瘤診斷市場前景

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按產品類型
    • 按技術
    • 按應用
    • 按癌症類型
    • 按最終用戶
    • 按國家
  • 中東和非洲：國家分析
    • 阿拉伯聯合大公國分子腫瘤學診斷
    • 沙烏地阿拉伯分子腫瘤學診斷產品
    • 南非分子腫瘤學診斷

第11 章：市場動態

  • 驅動因素
  • 挑戰

第12 章：市場趨勢與發展

第13 章：競爭格局

  • 業務概述
  • 產品供應
  • 近期發展
  • 財務狀況（報告）
  • 主要人員
    • Sysmex Corporation
    • F. Hoffmann-La Roche Ltd.
    • Myriad Genetics, Inc.
    • HTG Molecular Diagnostics, Inc.
    • Danaher Corporation.
    • QIAGEN NV
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • QIAGEN NV
    • Illumina, Inc.

第14 章：戰略建議

簡介目錄
Product Code: 15019

Global Molecular Oncology Diagnostics Market is anticipated to witness a steady CAGR in the forecast period, 2024-2028. This can be ascribed to the rising prevalence of various chronic diseases such as cancer, cardiovascular diseases, and diabetes, among others. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide, among which the males and females accounted for 10,065,305 and 9 227,484 cases, respectively. Cancer is caused due to uncontrolled proliferation of cancer cells that starts from the inner lining to the outer region. Molecular oncology diagnostics refers to the tests for diagnosing cancer. These tests are used to identify the genetic material, proteins, or associated chemicals and provide information on health or disease. However, there is a need for developing new diagnostic methods and instruments, which is further expected to drive the growth of the Molecular Oncology Diagnostics Market.

The growing prevalence of cancer cases, the advanced technological advancement with the highest accuracy and precision, and the growing awareness amongst the population globally are projected to propel the growth of the market. Additionally, the high cost of molecular diagnostic techniques is expected to hamper the growth of the Global Molecular Oncology Diagnostics Market in the forecast years.

Rising Prevalence of Cancer

Cancer is one of the most common causes of death in the world. The global increase in cancer cases is probably a factor in the oncology molecular diagnostics market's growth. In the United States of America in 2021, there were 1.8 million new instances of cancer and 0.6 million cancer deaths, according to the American Cancer Society. Due to the proliferation of cancerous cells, medical professionals are increasing their research and development efforts to develop treatments and diagnostics services to aid the prevention and treatment of cancer. Lung, prostate, bowel, and female breast cancer make up the top four cancer types worldwide, accounting for 43% of all new cancer cases, according to the American Cancer Society. For instance, the American Cancer Society estimates that there will be 106,180 new instances of colon cancer and 44,850 new cases of rectal cancer in the United States by the year 2022. Additionally, several professional associations, including the National Comprehensive Cancer Network (NCCN), the American Association of Clinical Oncology (ASCO), and the College of American Pathologists (CAP), have developed biomarker testing and treatment guidelines, according to the American Cancer Society's 2020 report. Therefore, their treatment or diagnostic imaging is responsible for propelling the growth of Global Molecular Oncology Diagnostic Market.

Advancement in Technology

The advanced technology constitutes the sequencing techniques of genomics. For instance, the advancement in cancer genome sequencing technology, computational analysis, tumor models, and innovation and research going on in modern cancer research institutes promote early detection of cancer and its mutation. For instance, in June 2020, the United States Food and Drug Administration (FDA) gave approval to Cobas EGFR Mutation Test, a mutation test for testing patients with non-small cell lung cancer is a real-time test that can identify cancer resistance mutations and 42 mutations in the EGFR gene, which codes for the epidermal growth factor receptor. This molecular test was developed by a US-based company, namely Roche Molecular Systems, Inc.

Recent Developments & Product Launches

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need for developing novel diagnostic solutions for the treatment of different life-threatening diseases like cancer. For instance, in August 2022, Guardant Health expanded its Guardant Reveal test usage and developed a liquid biopsy test for residual disease detection and recurrence monitoring, including early-stage breast and lung cancers. It is currently accessible to patients with breast and lung cancer and is the only tissue-free test for colorectal cancer (CRC).

Additionally, in December 2021, QIAGEN, in partnership with Denovo Biopharma, developed a companion diagnostic test for the treatment of diffuse large B-cell lymphoma. This test identified people who have the Denovo genomic marker 1 (DGM1), which responded to the Denovo cancer drug DB102.

Market Segmentation

Global Molecular Oncology Diagnostics Market can be segmented by product type, technology, application, cancer type, end user, region, and company. Based on product type, the market can be segmented into instruments, kits and assays, and software. Based on technology, the market is fragmented into fluorescence in-situ hybridization (FISH), next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), flow cytometry, and other technologies. Based on application, the market is fragmented into Research and Clinical. Based on cancer type, the market is fragmented into solid tumors and blood cancers. Based on end users, the market is segmented into hospitals and diagnostic centers, reference laboratories, pharmaceutical and biotechnology companies, and academic and research institutes.

Advancement in Technology and Product Launch

The market players in Global Molecular Oncology Diagnostics Market are adopting various natural and modified strategies for market growth and development. For instance, a 5-year extension of their US supply agreement for the Insured ONE (FIT) fecal immunochemistry test was announced in January 2022 by Clinical Genomics, an innovator in the development of colorectal cancer testing, and Quest Diagnostics (NYSE: DGX), the world's largest provider of diagnostic information services. By delivering InSure FIT and the new InSure ONE FIT for colorectal cancer diagnostic programs, this arrangement improves an ongoing partnership. Amgen and Plexium established a multi-year partnership to find new targeted protein degradation treatments in February 2022. The multi-year partnership aids in the development of innovative molecular glue therapies by utilizing knowledge gained from Amgen's experience in creating multi-specific compounds. Furthermore, several strategies like collaboration, partnerships, mergers, acquisitions, product launches, and technology development propel the growth of Global Molecular Oncology Diagnostic Market.

Company Profiles

Sysmex Corporation, F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., HTG Molecular Diagnostics, Inc., Danaher Corporation, QIAGEN N.V., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., QIAGEN N.V., Illumina, Inc., etc. are some of the key players operating in the global molecular oncology diagnostics market.

Report Scope

In this report, Global Molecular Oncology Diagnostics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Molecular Oncology Diagnostics Market, By Product Type:

  • Instruments
  • Kits and Assays
  • Software

Molecular Oncology Diagnostics Market, By Technology:

  • Fluorescence In-Situ Hybridization (FISH)
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Flow Cytometry
  • Other Technologies

Molecular Oncology Diagnostics Market, By Application:

  • Research
  • Clinical

Molecular Oncology Diagnostics Market, By Cancer Type:

  • Solid Tumor
    • Breast Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Other
  • Blood Cancers
    • Lymphoma
    • Leukemia
    • Multiple Myeloma
    • Others

Molecular Oncology Diagnostics Market, By End User:

  • Hospitals and Diagnostic Centers
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes

Molecular Oncology Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Molecular Oncology Diagnostics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molecular Oncology Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Instruments, Kits and Assays, Software)
    • 5.2.2. By Technology (Fluorescence In-Situ Hybridization (FISH), Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Flow Cytometry, and Other Technologies)
    • 5.2.3. By Application (Research, Clinical)
    • 5.2.4. By Cancer Type {Solid Tumor (Breast Cancer, Ovarian Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer, and Other Solid Tumors), Blood cancers (Lymphoma, Leukemia, Multiple Myeloma, and other Hematological Malignancies)}
    • 5.2.5. By End User (Hospitals and Diagnostic Centers, Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes)
    • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Product Type
    • 5.3.2. By Technology
    • 5.3.3. By Application
    • 5.3.4. By Cancer Type
    • 5.3.5. By End User
    • 5.3.6. By Region

6. North America Molecular Oncology Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technology
    • 6.2.3. By Application
    • 6.2.4. By Cancer Type
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Molecular Oncology Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By Cancer Type
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Molecular Oncology Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By Cancer Type
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Molecular Oncology Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By Cancer Type
        • 6.3.3.2.5. By End User

7. Europe Molecular Oncology Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By Cancer Type
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Molecular Oncology Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By Cancer Type
        • 7.3.1.2.5. By End User
    • 7.3.2. France Molecular Oncology Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By Cancer Type
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Molecular Oncology Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By Cancer Type
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Molecular Oncology Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By Cancer Type
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Molecular Oncology Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By Cancer Type
        • 7.3.5.2.5. By End User

8. Asia-Pacific Molecular Oncology Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By Cancer Type
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Molecular Oncology Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By Cancer Type
        • 8.3.1.2.5. By End User
    • 8.3.2. Japan Molecular Oncology Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By Cancer Type
        • 8.3.2.2.5. By End User
    • 8.3.3. India Molecular Oncology Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By Cancer Type
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Molecular Oncology Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By Cancer Type
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Molecular Oncology Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By Cancer Type
        • 8.3.5.2.5. By End User

9. South America Molecular Oncology Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By Cancer Type
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Molecular Oncology Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By Cancer Type
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Molecular Oncology Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By Cancer Type
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Molecular Oncology Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By Cancer Type
        • 9.3.3.2.5. By End User

10. Middle East and Africa Molecular Oncology Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By Cancer Type
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Molecular Oncology Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By Cancer Type
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Molecular Oncology Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By Cancer Type
        • 10.3.2.2.5. By End User
    • 10.3.3. South Africa Molecular Oncology Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By Cancer Type
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
    • 13.5.1. Sysmex Corporation
    • 13.5.2. F. Hoffmann-La Roche Ltd.
    • 13.5.3. Myriad Genetics, Inc.
    • 13.5.4. HTG Molecular Diagnostics, Inc.
    • 13.5.5. Danaher Corporation.
    • 13.5.6. QIAGEN N.V.
    • 13.5.7. Bio-Rad Laboratories, Inc.
    • 13.5.8. Agilent Technologies, Inc.
    • 13.5.9. QIAGEN N.V.
    • 13.5.10. Illumina, Inc.

14. Strategic Recommendations